Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.58 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4524539 | 1.00 | CYSLTR2 (0.58) | CYSLTR2CYSLTR1MCHR1POLBRAB9A | |
| SCHEMBL4512254 | 0.92 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1MCHR1POLBRAB9A | |
| SCHEMBL4512258 | 0.92 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1MCHR1POLBRAB9A | |
| SCHEMBL4521604 | 0.90 | CYSLTR2 (0.68) | CYSLTR2POLBRAB9AMAPTGRM5 | |
| SCHEMBL4522489 | 0.88 | CYSLTR2 (0.73) | CYSLTR2CYSLTR1MCHR1POLBRAB9A | |
| SCHEMBL4522480 | 0.88 | CYSLTR2 (0.73) | CYSLTR2CYSLTR1MCHR1POLBRAB9A | |
| SCHEMBL4507345 | 0.88 | CYSLTR2 (0.64) | CYSLTR2CYSLTR1MCHR1POLBRAB9A | |
| SCHEMBL4507341 | 0.88 | CYSLTR2 (0.64) | CYSLTR2CYSLTR1MCHR1POLBRAB9A | |
| SCHEMBL4513762 | 0.88 | CYSLTR2 (0.64) | CYSLTR2CYSLTR1MCHR1POLBRAB9A | |
| SCHEMBL4521894 | 0.86 | CYSLTR2 (0.78) | CYSLTR2POLBRAB9AMAPTGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-20060154912-A1 | Isophtalic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154912-A1 | Isophtalic acid derivatives | VHL, FABP3, CPT1A | CYSLTR2 1426/4885CYSLTR1 1675/4885MCHR1 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.